← Leaderboards
Pyong Woo Park
Baylor College Of Medicine
$19,694,248
Attributed
$20,161,689
Total exposure
16
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,161,689 · 16
By mechanism
R01$17,785,015 · 11
R21$2,376,674 · 5
Top collaborators
- Stella Kourembanas2 shared
- Jian None Liu2 shared
Others in their field
Top investigators on “Syndecan”
- Michael Simons · Yale University$16,808,420
- Alan C Rapraeger · University Of Wisconsin Madison$11,770,499
- Gordon William Laurie · University Of Virginia Charlottesville$9,632,610
- Bradley B Olwin · University Of Colorado At Boulder$7,763,454
- Ralph D Sanderson · University Of Arkansas Med Scis Ltl Rock$6,303,586
- Jeffrey D Esko · University Of California San Diego$6,056,594
Research focus
SyndecanCell SurfaceHeparitin SulfateHeparan Sulfate ProteoglycanTissuesNeutrophilMolecularInfectionMediatingIn VivoPathogenBiologicalPathogenesisWild Type MouseBaseExtracellularVirulenceCellsInjuryInflammatoryBindingEpithelial CellsExtracellular MatrixCytokine
Grant awards (54)
Glypicans in Bacterial Lung Infection$623,861
R01 · FY2025 · HL · contact PI
HSPG Interactions in Liver Disease$451,079
R01 · FY2025 · DK · contact PI
ECM Regulation of Ocular Surface Disease$442,500
R01 · FY2025 · EY · contact PI
Glypicans in Bacterial Lung Infection$623,861
R01 · FY2024 · HL · contact PI
ECM Regulation of Ocular Surface Disease$442,500
R01 · FY2024 · EY · contact PI
HSPG Interactions in Liver Disease$433,035
R01 · FY2024 · DK · contact PI
HSPG Interactions in Liver Disease$451,079
R01 · FY2023 · DK · contact PI
ECM Regulation of Ocular Surface Disease$442,500
R01 · FY2023 · EY · contact PI
HSPG Interactions in Liver Disease$451,079
R01 · FY2022 · DK · contact PI
ECM Regulation of Ocular Surface Disease$442,500
R01 · FY2022 · EY · contact PI
Subversion of Syndecan-1 Functions in Listeriosis$221,250
R21 · FY2022 · AI · contact PI
Syndecan Regulation of Sepsis Host Defense$501,434
R01 · FY2021 · HL · contact PI
Subversion of Syndecan-1 Functions in Listeriosis$265,500
R21 · FY2021 · AI · contact PI
Syndecan Regulation of Sepsis Host Defense$501,434
R01 · FY2020 · HL · contact PI
Proteoglycan-Chemokine Interactions in Lung Disease$485,256
R01 · FY2020 · HL · contact PI
Syndecan Regulation of Sepsis Host Defense$501,434
R01 · FY2019 · HL · contact PI
Proteoglycan-Chemokine Interactions in Lung Disease$485,256
R01 · FY2019 · HL · contact PI
Mesenchymal Stem Cell Regulation by Syndecan-1 in Lung Injury$221,250
R21 · FY2019 · AI
Syndecan Regulation of Sepsis Host Defense$501,434
R01 · FY2018 · HL · contact PI
Proteoglycan-Chemokine Interactions in Lung Disease$485,256
R01 · FY2018 · HL · contact PI
Mesenchymal Stem Cell Regulation by Syndecan-1 in Lung Injury$265,500
R21 · FY2018 · AI
Proteoglycan-Chemokine Interactions in Lung Disease$485,256
R01 · FY2017 · HL · contact PI
HSPGs in Alpha-toxin-induced Tissue Injury$221,250
R21 · FY2017 · AI · contact PI
HSPGs in Ocular Surface Diseases$391,500
R01 · FY2016 · EY · contact PI
HSPGs in Alpha-toxin-induced Tissue Injury$265,500
R21 · FY2016 · AI · contact PI
HSPGs in Ocular Surface Diseases$383,670
R01 · FY2015 · EY · contact PI
Syndecan Interactions in Lung Injury and Repair$426,300
R01 · FY2014 · HL · contact PI
HSPGs in Ocular Surface Diseases$383,670
R01 · FY2014 · EY · contact PI
Syndecan Interactions in Lung Injury and Repair$414,120
R01 · FY2013 · HL · contact PI
HSPGs in Ocular Surface Diseases$371,925
R01 · FY2013 · EY · contact PI
Syndecan Interactions in Lung Injury and Repair$435,000
R01 · FY2012 · HL · contact PI
Proteoglycans in Lung Innate Immunity and Host Defense$430,650
R01 · FY2012 · HL · contact PI
HSPGs in Ocular Surface Diseases$391,500
R01 · FY2012 · EY · contact PI
Proteoglycans in Lung Innate Immunity and Host Defense$434,166
R01 · FY2011 · HL · contact PI
Syndecan Interactions in Lung Injury and Repair$432,500
R01 · FY2011 · HL · contact PI
Proteoglycans in Lung Innate Immunity and Host Defense$429,584
R01 · FY2010 · HL · contact PI
Role of Syndecan-1 in S. aureus Pneumonia$212,541
R21 · FY2010 · AI · contact PI
Glycomics of Heparan Sulfate in Bacterial Pathogenesis$197,258
R21 · FY2010 · AI
Proteoglycans in Lung Innate Immunity and Host Defense$426,666
R01 · FY2009 · HL · contact PI
Role of Syndecan-1 in S. aureus Pneumonia$255,750
R21 · FY2009 · AI · contact PI
Glycomics of Heparan Sulfate in Bacterial Pathogenesis$250,875
R21 · FY2009 · AI
Proteoglycans in Sepsis$320,012
R01 · FY2008 · HL · contact PI
Proteoglycans in Sepsis$320,012
R01 · FY2007 · HL · contact PI
Proteoglycans in Sepsis$329,570
R01 · FY2006 · HL · contact PI
Proteoglycans in Lung Inflammation and Fibrosis$190,490
R01 · FY2006 · HL · contact PI
Proteoglycans in Lung Inflammation and Fibrosis$132,526
R01 · FY2006 · HL · contact PI
Proteoglycans in Sepsis$337,500
R01 · FY2005 · HL
Proteoglycans in Lung Inflammation and Fibrosis$330,800
R01 · FY2005 · HL
Proteoglycans in Microbial Pathogenesis and Host Defense$263,375
R01 · FY2005 · HL
Proteoglycans in Lung Inflammation and Fibrosis$330,800
R01 · FY2004 · HL
Proteoglycans in Microbial Pathogenesis and Host Defense$263,375
R01 · FY2004 · HL
Proteoglycans in Lung Inflammation and Fibrosis$337,800
R01 · FY2003 · HL
Proteoglycans in Microbial Pathogenesis and Host Defense$263,375
R01 · FY2003 · HL
Proteoglycans in Microbial Pathogenesis and Host Defense$263,375
R01 · FY2002 · HL